3SBio Bundle
What is the history of 3SBio?
3SBio Inc. has grown from its 1993 founding in China to become a major player in the biopharmaceutical industry. Its initial goal was to make important biopharmaceuticals, like Interferon, accessible and affordable.
The company, established as Shenyang Sunshine Pharmaceuticals Co., Ltd., has a strong foundation built on providing innovative and high-quality treatments. Today, it's a fully integrated biotechnology firm with a significant market presence.
3SBio's journey highlights its strategic growth and market leadership. The company's product portfolio covers key therapeutic areas such as oncology, nephrology, and immunology. A key product, TPIAO, dominated the thrombocytopenia treatment market in China in 2024 with a 66.6% share. Additionally, its recombinant human erythropoietin (rhEPO) products captured a 42.0% market share in the same year. For a deeper dive into the company's operational environment, consider a 3SBio PESTEL Analysis.
Financially, 3SBio demonstrated robust performance in 2024. Its annual revenue reached approximately RMB 9.108 billion, marking a 16.5% increase year-on-year. Net profit attributable to owners saw a substantial surge of 34.9%, reaching approximately RMB 2.09 billion.
What is the 3SBio Founding Story?
The story of 3SBio Inc. begins in 1993 with the establishment of Shenyang Sunshine Pharmaceuticals Co., Ltd. in Shenyang, China. This venture was spearheaded by Major General Lou Dan and his dedicated team, marking a significant step in China's burgeoning biotechnology sector.
The Genesis of 3SBio
Founded in 1993, 3SBio's origins are rooted in Shenyang, China, with the establishment of Shenyang Sunshine Pharmaceuticals Co., Ltd. Major General Lou Dan, a prominent bioengineering expert, led the founding team with a clear vision for accessible biopharmaceuticals.
- Founder: Major General Lou Dan
- Founding Year: 1993
- Initial Focus: Recombinant proteins and biopharmaceutical products
- Location: Shenyang, China
Lou Dan, a distinguished bioengineering medical expert and former director of the Institute of Microbiology and Immunology of Shenhou Military Medical Research Institute, brought considerable expertise to the nascent company. His leadership extended to serving as chairman, president, and chief engineer of the organization. The founding team recognized a crucial gap in China's healthcare system: the need for biopharmaceutical products that were both effective and affordable for the general population. This understanding fueled the company's early mission, with Lou Dan articulating in 2000 a powerful goal: 'To make the Interferon as affordable as penicillin for ordinary people.' This ambition underscored a commitment to democratizing access to vital biotherapeutics.
The initial business model for 3SBio was comprehensive, encompassing the research, development, manufacturing, and marketing of biopharmaceutical products, with a particular emphasis on recombinant proteins. A pivotal moment in the company's early history was the approval for manufacturing of its first major product, Intefen (recombinant human interferon α2a injection), in April 1995. This was followed by its market launch in December 1995. The significance of this product was quickly recognized, as it was subsequently included in the National Medical Insurance Catalogue as a Category B drug, a testament to its clinical value and accessibility. This early success provided a strong foundation for 3SBio's subsequent growth and development. While specific details regarding initial funding, such as bootstrapping or early seed rounds, are not extensively documented, the company benefited from the supportive environment for the biotechnology industry within China at the time, which facilitated its establishment and early trajectory. The company's journey reflects a commitment to innovation and accessibility, aligning with its Mission, Vision & Core Values of 3SBio.
3SBio SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of 3SBio?
Following its founding, the company experienced a period of significant growth and expansion, driven by strategic product introductions and market penetration. This early phase laid the groundwork for its future success in the biopharmaceutical sector.
Key Product Launches
After launching Intefen in 1995, the company introduced Inleusin in 1996. A major milestone was the 1998 launch of EPIAO, a recombinant human erythropoietin injection that became the leading brand in China's erythropoietin market by 2002.
Operational Footprint Expansion
By the end of 2024, the company had established four major R&D bases across China in Shenyang, Shanghai, Shenzhen, and Hangzhou, in addition to facilities in Como, Italy. This expansion supported the development of dual platforms for biological and chemical drug research.
Workforce and Market Reach Growth
As of December 31, 2024, the company's workforce grew to 5,577 employees. Its international presence expanded, with products sold in 20 countries in 2024, an increase from 25 countries in 2023.
Strategic Acquisitions and Financial Performance
Strategic acquisitions, such as the 2015 purchase of Zhejiang Wansheng Pharmaceutical for $83 million, strengthened its portfolio. Revenue grew consistently, reaching RMB 9.108 billion in 2024, a 16.5% year-on-year increase. The flagship product, TPIAO, saw sales of RMB 5.062 billion in 2024, up 20.4% year-on-year, reflecting strong market acceptance and contributing to the company's trajectory as a key player in the biopharmaceutical market. This period highlights a strong Growth Strategy of 3SBio.
3SBio PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in 3SBio history?
The 3SBio company history is marked by significant advancements in biotechnology, strategic collaborations, and a consistent drive for innovation. The company has successfully navigated the complexities of the biopharmaceutical industry, establishing itself as a key player. Its journey reflects a commitment to developing novel therapies and expanding its market reach, contributing to the growth of China's biotech sector.
| Year | Milestone |
|---|---|
| 2016 | Formed an exclusive licensing agreement with AstraZeneca for Type 2 diabetes drugs Byetta and Bydureon in China. |
| 2024 | Partnered with Haihe Biopharma for the commercialization rights of paclitaxel oral solution, Liporaxel, in China. |
| 2024 | Secured commercialization rights for Clifutinib from HEC and HER2-targeting ADC DB-1303 from Duality Biologics. |
| 2024 | Achieved an MSCI ESG rating of 'AA', surpassing 84% of global industry peers. |
| May 2025 | Entered into an exclusive global licensing agreement with Pfizer for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. |
3SBio's innovation is evident in its development of groundbreaking products like TPIAO, the world's sole commercialized recombinant human thrombopoietin, and Yisaipu, the first TNF-α inhibitor in Mainland China for rheumatic diseases. The company also developed Cipterbin, China's first innovative anti-HER2 monoclonal antibody with an enhanced Fc region.
TPIAO
The world's only commercialized recombinant human thrombopoietin (rhTPO) product, maintaining a dominant market share in China.
Yisaipu
The first-to-market Tumour Necrosis Factor (TNF)-α inhibitor in Mainland China for rheumatic diseases.
Cipterbin
The first innovative anti-HER2 monoclonal antibody in China with an engineered Fc region for enhanced efficacy.
Extensive Patent Portfolio
Applied for 285 patents for invention with 90 valid patents granted, underscoring a strong commitment to intellectual property.
Strategic Partnerships
Engaged in key collaborations, including a significant global licensing agreement with Pfizer for SSGJ-707 valued at an upfront payment of $1.25 billion.
Product Portfolio
Boasts a portfolio of over 30 listed products, with 22 classified as National New Drugs, showcasing a robust pipeline.
The company has operated within a highly competitive biopharmaceutical landscape, facing challenges such as the impact of global events like COVID-19. Despite these hurdles, 3SBio has demonstrated resilience and adaptability, maintaining growth in net profit.
Competitive Landscape
Navigated a dynamic and competitive biopharmaceutical market, requiring continuous adaptation and strategic planning.
Global Health Events
Managed the operational and financial impacts of global health crises, such as COVID-19, while ensuring business continuity.
Strategic Adaptation
Consistently adapted through strategic shifts, including expanding therapeutic coverage via internal R&D and external collaborations, as detailed in the Target Market of 3SBio analysis.
3SBio Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for 3SBio?
The 3SBio company history showcases a consistent trajectory of growth and innovation since its inception. Founded in 1993, the company has strategically expanded its product portfolio and market reach through key developments and acquisitions.
| Year | Key Event |
|---|---|
| 1993 | Shenyang Sunshine Pharmaceuticals Co., Ltd., later known as 3SBio, was established in Shenyang, China. |
| 1995 | Launched Intefen (recombinant human interferon α2a injection), which was subsequently included in the National Medical Insurance Catalogue. |
| 1996 | Inleusin (recombinant human interleukin-2 for injection) was listed. |
| 1998 | Introduced EPIAO (recombinant human erythropoietin injection), which became a leading rhEPO brand in China by 2002. |
| 2005 | Marketed Yisaipu, China's first antibody fusion protein for rheumatism. |
| 2015 | Acquired Zhejiang Wansheng Pharmaceutical for $83 million, marking its largest acquisition to date. |
| 2016 | Secured an exclusive license agreement with AstraZeneca for Byetta and Bydureon within China. |
| 2017 | Dr. Zhenping Zhu was appointed President of R&D and Chief Scientific Officer. |
| 2019 | Forged partnerships with Numab Therapeutics and Verseau to develop multi-specific and immuno-oncology therapies. |
| 2023 | Celebrated its 30th anniversary, with revenue experiencing over 20% year-on-year growth. |
| October 2024 | Entered a partnership with Haihe Biopharma for the commercialization rights of paclitaxel oral solution. |
| December 2024 | Reported a workforce of 5,577 employees and operations across Shenyang, Shanghai, Hangzhou, Shenzhen, and Como, Italy, with products distributed in 20 countries. |
| March 2025 | Announced 2024 annual results, showing revenue of RMB 9.108 billion (a 16.5% year-on-year increase) and net profit of RMB 2.09 billion (a 34.9% year-on-year increase). |
| May 2025 | Entered an exclusive global licensing agreement with Pfizer for SSGJ-707, a bispecific antibody, which includes a $1.25 billion upfront payment and potential milestones up to $4.8 billion. |
Strategic Growth Through R&D and Partnerships
3SBio is committed to a dual-track strategy, emphasizing internal research and development alongside external collaborations to fuel future growth. The company aims to accelerate innovation, particularly in its oncology pipeline, by advancing early discovery projects into clinical stages.
Advancing Clinical Trials and Therapeutic Areas
The company plans to continue the clinical progress of its autoimmune candidates and initiate the first Phase 3 study for SSGJ-707 in China during 2025. 3SBio also intends to actively pursue new drug development for conditions affecting large patient populations, such as hair loss, acne, and weight management.
Financial Projections and Market Outlook
Analysts project 3SBio's earnings to grow by 3% annually and revenue by 6.9% per year. The company is expected to achieve a return on equity of 12.9% within three years, reflecting its strong financial outlook and market position.
Global Ambitions and Patient Impact
With operations in multiple countries and products sold in 20 nations, 3SBio is focused on global expansion. Its ambition is to reach hundreds of millions of patients worldwide by developing accessible, high-quality therapies, aligning with its founding vision of improving patient outcomes.
3SBio Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of 3SBio Company?
- What is Growth Strategy and Future Prospects of 3SBio Company?
- How Does 3SBio Company Work?
- What is Sales and Marketing Strategy of 3SBio Company?
- What are Mission Vision & Core Values of 3SBio Company?
- Who Owns 3SBio Company?
- What is Customer Demographics and Target Market of 3SBio Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.